What do systematic reviews say?

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 43390 participants
  Moderate

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 43390 participants
  High

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

The review found no eligible studies for this question.

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

ChAdOx1 – AstraZeneca + University of Oxford showed no clear difference in all‐cause mortalityf compared with placebo (low certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 0.48 [0.2, 1.14]
  5 studies · 56727 participants
  Low

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

ChAdOx1 – AstraZeneca + University of Oxford probably leads to higher systemic reactogenicity eventsi compared with placebo (moderate certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 3.93 [2.11, 7.29]
  1 study · 256 participants
  Moderate

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 57580 participants
  Low

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

ChAdOx1 – AstraZeneca + University of Oxford showed no clear difference in serious adverse eventso compared with placebo (moderate certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 0.88 [0.72, 1.07]
  7 studies · 58182 participants
  Moderate

ChAdOx1 – AstraZeneca + University of Oxford vs placebo

ChAdOx1 – AstraZeneca + University of Oxford probably leads to higher local reactogenicity eventsi compared with placebo (moderate certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 6.44 [2.98, 13.92]
  1 study · 256 participants
  Moderate

SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford vs ChAdOx1 – University of Oxford

The review found no eligible studies for this question.

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford vs ChAdOx1 – University of Oxford

The review found no eligible studies for this question.

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford vs ChAdOx1 – University of Oxford

The review found no eligible studies for this question.

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford vs ChAdOx1 – University of Oxford

The review found no eligible studies for this question.

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford vs ChAdOx1 – University of Oxford

SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of… probably leads to lower systemic reactogenicity eventsb compared with chAdOx1 – University of Oxford (moderate certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 0.73 [0.54, 0.98]
  1 study · 400 participants
  Moderate

SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford vs ChAdOx1 – University of Oxford

SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of… showed no clear difference in any adverse evente compared with chAdOx1 – University of Oxford (low certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 0.83 [0.52, 1.33]
  1 study · 400 participants
  Low

SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford vs ChAdOx1 – University of Oxford

SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of… showed no clear difference in serious adverse eventsg compared with chAdOx1 – University of Oxford (low certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 0.5 [0.08, 2.95]
  1 study · 400 participants
  Low

SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford vs ChAdOx1 – University of Oxford

SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of… showed no clear difference in local reactogenicity eventsb compared with chAdOx1 – University of Oxford (low certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 0.76 [0.55, 1.05]
  1 study · 400 participants
  Low